Companies News
The
Market Quotes Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.
Medivir announces new studies in phase III program for TMC435:
- Study in previous non-responder Hepatitis C genotype-1 infected patients
- Study in Hepatitis C genotype-4 infected patients
Tuesday, 13 March 2012
Huddinge, Sweden – MedivirAB (OMX: MVIR) a research based specialty
pharmaceutical company focused on infectious diseases announces that
its oral, once daily investigational protease inhibitor TMC435,
developed by Janssen Pharmaceuticals for the treatment of Hepatitis C
virus (HCV), has commenced patient dosing and started screening in two
new phase III clinical trials, HPC3001 and HPC3011, respectively. See attachment for details
What do you think about this
article or us? Please leave a comment. Thank you!
